N/A N=186 Randomized Prevention

Preventing Addiction Related Suicide (PARS)

Suicide · Substance-Related Disorders

Bottom Line

View on ClinicalTrials.gov: NCT03166709 ↗

Enrolled (actual)

186

Serious AEs

0.5%

Results posted

Aug 2025

Primary outcome: Primary: PARS Help-Seeking Scale — 0.57; 0.53 units on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Preventing Addiction Related Suicide (PARS) (Behavioral); Intensive Outpatient Program standard session (Behavioral)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Washington
Primary completion: May 2020

Outcome Measures

Outcome	Result	p-value
PRIMARY PARS Help-Seeking Scale	0.57; 0.53	—
PRIMARY PARS Suicide Knowledge Scale	7.47; 8.24	—
PRIMARY PARS Attitude Scale	12.29; 11.14	—
SECONDARY Suicidal Behavior Questionnaire - Revised	4.54; 4.82	—

Summary

The goal of this study is to evaluate the effectiveness and utility of the investigator's National Institute on Drug Abuse (NIDA) R21 developed "Preventing Addiction Related Suicide" (PARS) program by utilizing a novel stepped wedge design to evaluate PARS as a selected prevention program to increase help-seeking by clients in community addiction treatment.

Eligibility Criteria

Inclusion Criteria

Enrolled client in one of the community treatment settings
Over 18 years of age (no maximum age)
Ability to understand written and spoken English

Exclusion Criteria

Any clinical medical/psychiatric condition, severity of that condition, or life situation that in the opinion of the counselors or Drs. Comtois or Ries would compromise safe and voluntary study participation (e.g., psychosis, custody conflict). This is expected to be a rare circumstance and will be known prior to the recruitment session. If a counselor does not want someone involved, they will not be. If counselor is unsure, Dr. Comtois or Ries will facilitate decision with counselor ahead of time to assist in the decision.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03166709). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.